title: [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
authors.affiliation: AUO Geschäftsstelle, Seestr. 11, 17252, Schwarz, Deutschland. AUO@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
authors.affiliation: Organgruppe Blasenkarzinom, Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e.V., Kuno-Fischer-Str. 8, 14057, Berlin, Deutschland.
authors.forename: C-H
authors.initials: CH
authors.lastname: Ohlmann
authors.affiliation: Klinische Prüfung (LKP), TU München, Klinikum r. d. I., Ismaninger Str. 22, 81675, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Retz
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D002295:Carcinoma, Transitional Cell; D004359:Drug Therapy, Combination; D006801:Humans; D010984:Platinum / Q000627:therapeutic use*; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019459:Urothelium / Q000187:drug effects* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D010984:Platinum; C582435:pembrolizumab